A Study of PRT2527 in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Primary malignancies of the CNS, or uncontrolled CNS metastases, including impending spinal cord compression
• •have a corrected QT interval \>480 msec from prior or baseline
• •have impaired cardiac function or clinically significant cardiac disease
• •Treatment with strong inhibitors or inducers of CYP3A4
• •Prior exposure to a CDK9 inhibitor
• •History of another malignancy except for:
• •1. Curatively treated malignancy with no known active disease
• •2. Curatively treated non-melanoma skin cancer without evidence of disease
• •3. Curatively treated carcinoma in situ without evidence of disease
• •have undergone major surgery within 2 weeks prior to Week 1 Day 1
• •have had chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 28 days (whichever is shorter) prior to administration of the first dose of study drug on Week 1 Day 1.